Dublin, June 02, 2023 (GLOBE NEWSWIRE) -- The "Global Companion Diagnostics Partnering Terms and Agreements 2010-2023" report has been added to ResearchAndMarkets.com's offering.
The Global Companion Diagnostics Partnering Terms and Agreements 2010-2023 report provides comprehensive access to available deals and contract documents for over 550 companion diagnostics deals and agreements entered into by the worlds leading healthcare companies.
The report provides a detailed understanding and analysis of how and why companies enter companion diagnostics partnering deals. These deals tend to be multicomponent, starting with collaborative R&D, and proceed to commercialization of outcomes.
The report takes the reader through a comprehensive review companion diagnostics deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering companion diagnostics partnering deals.
The report presents financial deal term values for companion diagnostics deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.
The middle section of the report explores the leading dealmakers in the companion diagnostics partnering field; both the leading deal values and most active companion diagnostics dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.
One of the key highlights of the report is that over 550 online deal records of actual companion diagnostics deals, as disclosed by the deal parties, are included towards the end of the report in a directory format - by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.
In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.
The initial chapters of this report provide an orientation of companion diagnostics dealmaking. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in companion diagnostics dealmaking since 2010, including details of headline, upfront, milestone and royalty terms.
Chapter 3 provides a review of the leading companion diagnostics deals since 2010. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 4 provides a comprehensive listing of the top 25 most active companies in companion diagnostics dealmaking with a brief summary followed by a comprehensive listing of companion diagnostics deals announced by that company, as well as contract documents, where available.
Chapter 5 provides a comprehensive and detailed review of companion diagnostics partnering deals signed and announced since Jan 2010, where a contract document is available in the public domain. Each deal title links via Weblink to an online version of the deal record and contract document, providing easy access to each contract document on demand.
Chapter 6 provides a comprehensive and detailed review of companion diagnostics partnering deals signed and announced since Jan 2010. The chapter is organized by specific companion diagnostics technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.
A comprehensive series of appendices is provided organized by companion diagnostics partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.
The report also includes numerous tables and figures that illustrate the trends and activities in companion diagnostics partnering and dealmaking since 2010.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of companion diagnostics technologies and products.
Key benefits
Global Companion Diagnostics Partnering Terms and Agreements 2010-2023 report provides the reader with the following key benefits:
- In-depth understanding of companion diagnostics deal trends since 2010
- Access to headline, upfront, milestone and royalty data
- Detailed access to actual companion diagnostics contracts entered into by leading biopharma companies
- Identify most active companion diagnostics dealmakers since 2010
- Insight into terms included in companion diagnostics partnering agreement, with real world examples
- Understand the key deal terms companies have agreed in previous deals
- Undertake due diligence to assess suitability of your proposed deal terms for partner companies
In Global Companion Diagnostics Partnering Terms and Agreements 2010-2023, the available deals are listed by:
- Company A-Z
- Headline value
- Stage of development at signing
- Deal component type
- Specific therapy target
- Technology type
Analyzing actual contract agreements allows assessment of the following:
- What are the precise rights granted or optioned?
- What is actually granted by the agreement to the partner company?
- What exclusivity is granted?
- What is the payment structure for the deal?
- How are sales and payments audited?
- What is the deal term?
- How are the key terms of the agreement defined?
- How are IPRs handled and owned?
- Who is responsible for commercialization?
- Who is responsible for development, supply, and manufacture?
- How is confidentiality and publication managed?
- How are disputes to be resolved?
- Under what conditions can the deal be terminated?
- What happens when there is a change of ownership?
- What sublicensing and subcontracting provisions have been agreed?
- Which boilerplate clauses does the company insist upon?
- Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
- Which jurisdiction does the company insist upon for agreement law?
Companies Mentioned
- Max Planck Institute for Infection Biology
- Nicholas Conor Institute for Pediatric Cancer Research
- Astellas Pharma
- Astellas Pharma US
- Translational Drug Development
- IncellDx
- Seattle Genetics
- The Fleury Group
- Singulex
- WAVE Life Sciences
- RedHill Biopharma
- Cornell University
- HistologiX
- Cephalon
- Q2 Solutions
- Inform Genomics
- Inserm Transfert
- Merrimack Pharmaceuticals
- USBiomarkers
- CombiMatrix
- Epizyme
- Genzyme
- Exosome Diagnostics
- OrigiMed
- Q BioMed
- Informed Data Systems
- NeuroMetrix
- Pure MHC
- Epitomics
- IMIDomics
- Astrimmune
- Multimmune
- Biogen
- Qiagen
- QIAGEN (Suzhou) Translational Medicine Center
- Fusion Antibodies
- Aushon BioSystems
- Shuwen Biotech
- German Cancer Research Center
- Becton Dickinson
- German Federal Ministry of Education and Research
- London Genetics
- Golden Helix
- Gibson Oncology
- Dalton Pharma Services
For more information about this report visit https://www.researchandmarkets.com/r/x01nyr
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
